| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/05/2024 | 12:25 | GlobeNewswire Inc. | Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider | NASDAQ:GNTA | Genenta Science SPA |
| 12/02/2024 | 22:05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GNTA | Genenta Science SPA |
| 08/02/2024 | 11:00 | GlobeNewswire Inc. | Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors | NASDAQ:GNTA | Genenta Science SPA |
| 20/10/2023 | 22:15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GNTA | Genenta Science SPA |
| 06/09/2023 | 13:00 | GlobeNewswire Inc. | Genenta to Present at Upcoming Scientific and Investor Conferences | NASDAQ:GNTA | Genenta Science SPA |
| 28/07/2023 | 09:00 | GlobeNewswire Inc. | Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments | NASDAQ:GNTA | Genenta Science SPA |
| 29/06/2023 | 13:00 | GlobeNewswire Inc. | The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma | NASDAQ:GNTA | Genenta Science SPA |
| 25/05/2023 | 12:04 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:GNTA | Genenta Science SPA |
| 16/05/2023 | 13:00 | GlobeNewswire Inc. | Genenta to Provide Update on Lead Product Temferon™ | NASDAQ:GNTA | Genenta Science SPA |
| 12/05/2023 | 23:13 | Edgar (US Regulatory) | Securities Registration (foreign Private Issuer) (f-3) | NASDAQ:GNTA | Genenta Science SPA |
| 01/05/2023 | 22:06 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 26/04/2023 | 13:00 | GlobeNewswire Inc. | Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing | NASDAQ:GNTA | Genenta Science SPA |
| 21/04/2023 | 23:23 | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:GNTA | Genenta Science SPA |
| 10/02/2023 | 12:10 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:GNTA | Genenta Science SPA |
| 27/10/2022 | 00:45 | TipRanks | Maxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA) | NASDAQ:GNTA | Genenta Science SPA |
| 25/07/2022 | 12:00 | GlobeNewswire Inc. | AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative | NASDAQ:GNTA | Genenta Science SPA |
| 15/06/2009 | 16:47 | PR Newswire (US) | The following is an investment opinion release issued by EmergingStockReport.com | NASDAQ:GNTA | |
| 15/05/2009 | 16:48 | PR Newswire (US) | Stock Alerts on Market Movers: NGRN, RMBS, NVLS, LVS, GNTA, AN; Issued by Beacon Equity | NASDAQ:GNTA | |
| 07/03/2009 | 01:36 | Dow Jones News | Genta: FDA Favors Clinical Trial For Leukemia Drug Genasense | NASDAQ:GNTA | Genta Inc. |
| 07/03/2009 | 00:34 | Business Wire | FDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory ... | NASDAQ:GNTA | Genenta Science SPA |
| 13/02/2009 | 22:10 | Business Wire | Genta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate Highlights | NASDAQ:GNTA | Genenta Science SPA |
| 07/01/2009 | 19:02 | PR Newswire (US) | Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTA | NASDAQ:GNTA | |
| 15/09/2008 | 14:05 | PR Newswire (US) | Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma | NASDAQ:GNTA | |
| 07/08/2008 | 14:00 | PR Newswire (US) | Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights | NASDAQ:GNTA | |
| 31/07/2008 | 14:00 | PR Newswire (US) | Genta Announces Second Quarter 2008 Financial Results and Conference Call | NASDAQ:GNTA | |
| 15/07/2008 | 15:20 | PR Newswire (US) | BeaconEquity.com Issues TraderNotes on Active Stocks: CELI, UVSE, GSPG, GNTA, AAPL, IMMU, EXAS, EEE | NASDAQ:GNTA | |
| 14/07/2008 | 14:05 | PR Newswire (US) | FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia | NASDAQ:GNTA | |
| 08/07/2008 | 17:00 | PR Newswire (US) | BeaconEquity.com Issues TraderNotes on Active Stocks: REGRF, PASO, QMNM, UAUA, CBAK, SMOD, GNTA, YHOO | NASDAQ:GNTA | |
| 03/07/2008 | 16:20 | PR Newswire (US) | BeaconEquity.com Issues TraderNotes on Active Stocks: ERII, EXTR, IDXX, NSTR, CMLS, JAKK, MPWR, GNTA | NASDAQ:GNTA | |
| 24/06/2008 | 14:00 | PR Newswire (US) | Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma | NASDAQ:GNTA | |